A Phase 2 interventional study of eltrombopag and rabbit anti-thymocyte globulin (r-ATG) in Severe Aplastic Anemia (SAA), sponsored by Novartis Pharmaceuticals. Completed at 12 sites in 4 countries. Open to participants aged 6 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing eltrombopag in Anemia, Aplastic — 3 open to participants now, 3 under way, 1 of them phase 3. eltrombopag · Anemia, Aplastic.
Among the 17 studies testing eltrombopag in Anemia, Aplastic, this one is the 9th largest by enrollment, is one of 3 that started in 2020, is one of 11 in phase 2, and was the 14th registered.
372 studies on the registry are indexed under Anemia, Aplastic; 99 are open to participants now.
Browse Anemia, Aplastic studies →3 of the 17 studies testing eltrombopag in Anemia, Aplastic are open now, in 2 countries. Recruiting first, the newest first:
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 3–99
Melbourne Health · Sites in Australia
Ages 18+
Assiut University
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 59 Anemia, Aplastic studies recruiting now, 21 (36%) set no upper age limit and 30 (51%) stop at 75 or younger; 38 take children under 18; 5 take healthy volunteers.
This study: 6 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 14 · Phase 3 4
First in 2009; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is close to the median of 37 across 281 interventional studies indexed under Anemia, Aplastic.
Median enrollment 36 across the 17 interventional studies. Of the 13 that completed or were terminated, 11 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 17 have an industry lead sponsor. The 8 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
14 studies in Anemia, Aplastic by Novartis: 1 open now, 1 under way, none of them phase 3. Of 12 finished, 7 (58%) have results posted.
Among the 14 studies in Anemia, Aplastic by Novartis, this one is the only one that started in 2020, is one of 7 in phase 2, and was the 9th registered.
Novartis’s Anemia, Aplastic studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing eltrombopag in Anemia, Aplastic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 14 in Anemia, Aplastic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was designed to evaluate the efficacy and safety of eltrombopag when added to r-ATG and CsA in treatment naive East-Asian adult and pediatric patients with severe aplastic anemia (SAA).
This was a non-randomized, open label, single arm, multi-center, Phase II study to evaluate the efficacy and safety of eltrombopag in combination with immunosuppressive therapy (IST) regimen of r-ATG + CsA in East-Asian patients with severe aplatsic anemia who had not received prior IST.
Eligible participants were enrolled into the study and received eltrombopag (from Day 1 to Week 26) concomitantly with r-ATG (on Days 1-5) and CsA (from Day 1 to Week 26) in the core treatment part.
Participants who were assessed as responders (meeting complete (CR) or partial (PR) response criteria) at Week 26 were eligible for the extension part of the study and continued treatment with eltrombopag and CsA after Week 26 up to Week 52. During the extension part, eltrombopag treatment was provided up to Week 52. CsA was maintained or tapered at the investigator's discretion according to local practice, with a total duration of at least 2 years (18 months after Week 26). There was a 30 days after end of treatment safety follow-up at the end of the extension part.
All participants were offered to enter the long term follow-up after the discontinuation of eltrombopag, with yearly efficacy and clonal evolution assessments up to Year 3 (Week 156).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received eltrombopag in combination with r-ATG and CsA. * Eltrombopag was administered orally once daily with initial doses of 75mg/day for ≥ 12 years old and 37.5 mg/day for participants between ≥ 6 and \< 12 years. Doses could be adjusted based on platelet count * r-ATG was administered intravenously at a dose of 2.5 to 3.5 mg/kg/day on Days 1-5 * CsA was administered orally every 12 h at a starting dose of 3-6 mg/kg/day
Drug: eltrombopag · Drug: rabbit anti-thymocyte globulin (r-ATG) · Drug: cyclosporine A (CsA)
Tablet 25mg and 12.5mg
Also known as: ETB115
r-ATG 25 mg sterile lyophilized powder in 10 mL vials for IV use
Also known as: r-ATG
CsA 25mg Capsule or CsA 5.0g/50mL solution for oral use
Also known as: CsA
Complete Response (CR) Rate at Week 26
Complete response rate was defined as percentage of patients achieving complete response (CR). Complete response was defined as subjects meeting all the three criteria on two consecutive serial blood count measurements at least one week apart but not more than four weeks apart: * Absolute neutrophil count \> 1.0 ×10\^9/L * Platelet count \> 100 ×10\^9/L * Hemoglobin \> 100 g/L The participants who discontinued from the trial before Week 26 and those that received blood products prior to response assessment (7 days prior for platelet transfusions, 14 days for RBC transfusion and 21 days for growth factors) were treated as non-responders.
Time frame: Week 26 (6 months after starting study treatment)
Complete Response (CR) Rate
Complete response rate was defined as percentage of patients achieving complete response (CR). Complete response was defined as subjects meeting all the three criteria on two consecutive serial blood count measurements at least one week apart but not more than four weeks apart: * Absolute neutrophil count \> 1.0 ×10\^9/L * Platelet count \> 100 ×10\^9/L * Hemoglobin \> 100 g/L The participants who discontinued from the trial before Week 26 and those that received blood products prior to response assessment (7 days prior for platelet transfusions, 14 days for RBC transfusion and 21 days for growth factors) were treated as non-responders.
Time frame: Week 13 (3 months), Week 52 (12 months) and yearly after up to 3 years
Overall Response (ORR) Rate
Overall response rate was defined as percentage of patients achieving complete response (CR) or partial response (PR). Partial response (PR) was defined as blood counts no longer meeting the standard criteria for severe pancytopenia in SAA, equivalent to at least 2 of the 3 criteria below, but not sufficient for a CR: * Absolute neutrophil count ≥ 0.5 × 10\^9/L * Platelet count ≥ 20 × 10\^9/L * Reticulocyte count ≥ 20 × 10\^9/L Complete response (CR) was defined as subjects meeting all the three criteria on two consecutive serial blood count measurements at least one week apart but not more than four weeks apart: * Absolute neutrophil count \> 1.0 ×10\^9/L * Platelet count \> 100 ×10\^9/L * Hemoglobin \> 100 g/L
Time frame: Week 13 (3 months), 26 weeks (6 months), 52 weeks and yearly after up to 3 years
Duration of Complete Response
Duration of response was derived as the time from first documented and confirmed complete response (CR) until the time of relapse or death, whichever occurred first. Duration of response was estimated using Kaplan-Meier method. Clinical relapse was considered as the occurrence of any of the following events in a participant who had achieved a hematological response (CR) but had subsequently lost response (not explained by any other independent concomitant medical conditions) in one blood count measurements: * Meeting again the criteria for SAA * Requirement for transfusion again for subjects who had been transfusion independent * Decrease in any of the peripheral blood counts to absolute neutrophil count \< 0.5 x10\^9/L or platelets \< 20 x10\^9/L.
Time frame: Up to aproximately 3 years
Duration of Overall Response
Duration of response was derived as the time from first documented and confirmed response (either CR or PR) until the time of relapse or death, whichever occurred first. Duration of response was estimated using Kaplan-Meier method. Clinical relapse was considered as the occurrence of any of the following events in a participant who had achieved a hematological response (CR or PR) but had subsequently lost response (not explained by any other independent concomitant medical conditions) in one blood count measurements: * Meeting again the criteria for SAA * Requirement for transfusion again for subjects who had been transfusion independent * Decrease in any of the peripheral blood counts to absolute neutrophil count \< 0.5 x10\^9/L or platelets \< 20 x10\^9/L.
Time frame: Up to aproximately 3 years
Overall Survival (OS)
OS was defined as the time from the date of the first dose of study treatment to the date of death due to any cause. If a subject was not known to have died, survival was censored at the date of last contact. The distribution function of OS was estimated using the Kaplan- Meier method.
Time frame: Up to approximately 3 years
Overall Survival (OS) Rate
OS was defined as the time from the date of the first dose of study treatment to the date of death due to any cause. The OS rate is the estimated probability that a patient will remain event-free up to the specified time point and was obtained from the Kaplan-Meier survival estimates. If a subject was not known to have died, survival was censored at the date of last contact.
Time frame: Week 26, Week 52 and yearly after up to 3 years
Red Blood Cells (RBC) and Platelet Transfusion-free Interval Before Week 13 and 26
Transfusion-free interval was defined as the time from most recent RBC/platelet transfusion preceding response assessment to the date of response assessment.
Time frame: Week 13, 26
Percentage of Participants Who Become RBC Transfusion Independent
Transfusion independent participants were defined as those participants who were transfusion dependent at baseline but became transfusion free for a period of ≥ 8 weeks post-baseline for RBCs.
Time frame: From date of first dose to approximately 3 years
Percentage of Participants Who Become Platelet Transfusion Independent
Transfusion independent participants were defined as those participants who were transfusion dependent at baseline but became transfusion free for a period of ≥ 4 weeks post-baseline for platelets.
Time frame: From date of first dose to approximately 3 years
Time From the Date of First Dose of Investigational Treatment to the Date of First Occurrence of Any Clonal Evolution Events
Clonal evolution events were assessed by karyotyping (G-banding) and FISH (Fluorescence in situ hybridization) targeting abnormalities including, but not restricted to chromosome 3q del,5q del, monosomy 7, trisomy 8 and those associated with SAA (Severe aplastic anemia), MDS (Myelodysplastic syndrome), AML (Acute myeloid leukemia). Time to clonal evolution was to be estimated using the Kaplan-Meier method.
Time frame: From date of first dose to approximately 3 years
Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: AUClast
AUClast is the area under the curve from time zero to the last measurable concentration sampling time. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach.
Time frame: Pre-dose, and 2, 4, 6, 8 and 24 hours post-dose on Day 14 after initial dose
Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: AUCtau
AUCtau is area under the curve calculated to the end of a dosing interval (tau) at steady-state Blood samples were collected from patients to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach.
Time frame: Pre-dose, and 2, 4, 6, 8 and 24 hours post-dose on Day 14 after initial dose
Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: Ctrough
Cthrough is the pre-dose concentration at the end of dose interval. Blood samples were collected to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach. Eltrombopag was administered orally once daily with initial doses of 75mg/day for ≥ 12 years old and 37.5 mg/day for participants between ≥ 6 and \< 12 years. Doses could be adjusted based on platelet count every 2 weeks by decreasing it by 25 mg/day (12.5 mg/day, for participants below 12 years old) if the platelet count was above 200×10\^9/L. or interrupted if platelet count rose above 400×10\^9/L. In partial response participants dose could be restarted or increased to that before the decrease if platelet counts \< 30 x10\^9/L, Hb\< 90 g/L, ANC\< 0.5 x 10\^9/L or participant needed transfusion. In complete response participants dose could be restarted or increased to that before decrease if blood counts dropped to not meet CR criteria.
Time frame: Pre-dose on day 15 after initation of eltrombopag and and pre-dose on the 15th day after each new dose up to week 26
Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: Cmax
Cmax is the The maximum (peak) observed plasma drug concentration after dose administration. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach.
Time frame: Pre-dose, and 2, 4, 6, 8 and 24 hours post-dose on Day 14 after initial dose
Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: Tmax
Tmax is the time to reach maximum (peak) plasma drug concentration after dose administration. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach.
Time frame: Pre-dose, and 2, 4, 6, 8 and 24 hours post-dose on Day 14 after initial dose
Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: CLss/F
CLss/F is Apparent systemic (or total body) clearance at steady state from plasma. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach.
Time frame: Pre-dose, and 2, 4, 6, 8 and 24 hours post-dose on Day 14 after initial dose
Participants were enrolled at 12 sites in 4 different countries
| Milestone | Eltrombopag |
|---|---|
| Started | 36 |
| Started extension part | 28 |
| Started long term follow up | 34 |
| Completed | 28 |
| Not completed | 8 |
| Withdrew: Guardian decision | 1 |
| Withdrew: Participant decision | 4 |
| Withdrew: Death | 3 |
Complete response rate was defined as percentage of patients achieving complete response (CR). Complete response was defined as subjects meeting all the three criteria on two consecutive serial blood count measurements at least one week apart but not more than four weeks apart: * Absolute neutrophil count \> 1.0 ×10\^9/L * Platelet count \> 100 ×10\^9/L * Hemoglobin \> 100 g/L The participants who discontinued from the trial before Week 26 and those that received blood products prior to response assessment (7 days prior for platelet transfusions, 14 days for RBC transfusion and 21 days for growth factors) were treated as non-responders.
| percentage of participants | Eltrombopag |
|---|---|
| All participants | 16.7 (6.4 to 32.8) |
| < 18 years | 25 (3.2 to 65.1) |
| 18-64 years | 15.4 (4.4 to 34.9) |
| ≥ 65 years | 0 (0.0 to 84.2) |
Complete response rate was defined as percentage of patients achieving complete response (CR). Complete response was defined as subjects meeting all the three criteria on two consecutive serial blood count measurements at least one week apart but not more than four weeks apart: * Absolute neutrophil count \> 1.0 ×10\^9/L * Platelet count \> 100 ×10\^9/L * Hemoglobin \> 100 g/L The participants who discontinued from the trial before Week 26 and those that received blood products prior to response assessment (7 days prior for platelet transfusions, 14 days for RBC transfusion and 21 days for growth factors) were treated as non-responders.
| percentage of participants | Eltrombopag |
|---|---|
| Week 13 | 5.6 (0.7 to 18.7) |
| Week 52 | 30.6 (16.3 to 48.1) |
| Year 2 | 30.6 (16.3 to 48.1) |
| Year 3 | 30.6 (16.3 to 48.1) |
Overall response rate was defined as percentage of patients achieving complete response (CR) or partial response (PR). Partial response (PR) was defined as blood counts no longer meeting the standard criteria for severe pancytopenia in SAA, equivalent to at least 2 of the 3 criteria below, but not sufficient for a CR: * Absolute neutrophil count ≥ 0.5 × 10\^9/L * Platelet count ≥ 20 × 10\^9/L * Reticulocyte count ≥ 20 × 10\^9/L Complete response (CR) was defined as subjects meeting all the three criteria on two consecutive serial blood count measurements at least one week apart but not more than four weeks apart: * Absolute neutrophil count \> 1.0 ×10\^9/L * Platelet count \> 100 ×10\^9/L * Hemoglobin \> 100 g/L
| percentage of participants | Eltrombopag |
|---|---|
| Week 13 | 66.7 (49.0 to 81.4) |
| Week 26 | 77.8 (60.8 to 89.9) |
| Week 52 | 66.7 (49.0 to 81.4) |
| Year 2 | 50.0 (32.9 to 67.1) |
| Year 3 | 41.7 (25.5 to 59.2) |
Duration of response was derived as the time from first documented and confirmed complete response (CR) until the time of relapse or death, whichever occurred first. Duration of response was estimated using Kaplan-Meier method. Clinical relapse was considered as the occurrence of any of the following events in a participant who had achieved a hematological response (CR) but had subsequently lost response (not explained by any other independent concomitant medical conditions) in one blood count measurements: * Meeting again the criteria for SAA * Requirement for transfusion again for subjects who had been transfusion independent * Decrease in any of the peripheral blood counts to absolute neutrophil count \< 0.5 x10\^9/L or platelets \< 20 x10\^9/L.
| months | Eltrombopag |
|---|---|
| Duration of Complete Response | NA (NA to NA) |
Duration of response was derived as the time from first documented and confirmed response (either CR or PR) until the time of relapse or death, whichever occurred first. Duration of response was estimated using Kaplan-Meier method. Clinical relapse was considered as the occurrence of any of the following events in a participant who had achieved a hematological response (CR or PR) but had subsequently lost response (not explained by any other independent concomitant medical conditions) in one blood count measurements: * Meeting again the criteria for SAA * Requirement for transfusion again for subjects who had been transfusion independent * Decrease in any of the peripheral blood counts to absolute neutrophil count \< 0.5 x10\^9/L or platelets \< 20 x10\^9/L.
| months | Eltrombopag |
|---|---|
| Duration of Overall Response | NA (3.1 to NA) |
OS was defined as the time from the date of the first dose of study treatment to the date of death due to any cause. If a subject was not known to have died, survival was censored at the date of last contact. The distribution function of OS was estimated using the Kaplan- Meier method.
| Months | Eltrombopag |
|---|---|
| Overall Survival (OS) | NA (NA to NA) |
OS was defined as the time from the date of the first dose of study treatment to the date of death due to any cause. The OS rate is the estimated probability that a patient will remain event-free up to the specified time point and was obtained from the Kaplan-Meier survival estimates. If a subject was not known to have died, survival was censored at the date of last contact.
| percent probability | Eltrombopag |
|---|---|
| Week 26 | 97.2 (81.9 to 99.6) |
| Week 52 | 97.2 (81.9 to 99.6) |
| Year 2 | 94.1 (78.3 to 95.5) |
| Year 3 | 90.9 (74.4 to 97.0) |
Transfusion-free interval was defined as the time from most recent RBC/platelet transfusion preceding response assessment to the date of response assessment.
| days | Eltrombopag |
|---|---|
| RBC transfusion-free interval - Week 13 | 36.3 ± 25.62 |
| RBC transfusion-free interval - Week 26 | 98.9 ± 57.97 |
| Platelet transfusion-free interval - Week 13 | 34.0 ± 25.64 |
| Platelet transfusion-free interval - Week 26 | 97.3 ± 58.93 |
Transfusion independent participants were defined as those participants who were transfusion dependent at baseline but became transfusion free for a period of ≥ 8 weeks post-baseline for RBCs.
| percentage of participants | Eltrombopag |
|---|---|
| Percentage of Participants Who Become RBC Transfusion Independent | 86.2 |
Transfusion independent participants were defined as those participants who were transfusion dependent at baseline but became transfusion free for a period of ≥ 4 weeks post-baseline for platelets.
| percentage of participants | Eltrombopag |
|---|---|
| Percentage of Participants Who Become Platelet Transfusion Independent | 88.2 |
Clonal evolution events were assessed by karyotyping (G-banding) and FISH (Fluorescence in situ hybridization) targeting abnormalities including, but not restricted to chromosome 3q del,5q del, monosomy 7, trisomy 8 and those associated with SAA (Severe aplastic anemia), MDS (Myelodysplastic syndrome), AML (Acute myeloid leukemia). Time to clonal evolution was to be estimated using the Kaplan-Meier method.
| weeks | Eltrombopag |
|---|---|
| Time From the Date of First Dose of Investigational Treatment to the Date of First Occurrence of Any Clonal Evolution Events | NA (NA to NA) |
AUClast is the area under the curve from time zero to the last measurable concentration sampling time. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach.
| ng*h/mL | Eltrombopag |
|---|---|
| Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: AUClast | 602000 ± 239000 |
AUCtau is area under the curve calculated to the end of a dosing interval (tau) at steady-state Blood samples were collected from patients to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach.
| ng*h/mL | Eltrombopag |
|---|---|
| Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: AUCtau | 585000 ± 231000 |
Cthrough is the pre-dose concentration at the end of dose interval. Blood samples were collected to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach. Eltrombopag was administered orally once daily with initial doses of 75mg/day for ≥ 12 years old and 37.5 mg/day for participants between ≥ 6 and \< 12 years. Doses could be adjusted based on platelet count every 2 weeks by decreasing it by 25 mg/day (12.5 mg/day, for participants below 12 years old) if the platelet count was above 200×10\^9/L. or interrupted if platelet count rose above 400×10\^9/L. In partial response participants dose could be restarted or increased to that before the decrease if platelet counts \< 30 x10\^9/L, Hb\< 90 g/L, ANC\< 0.5 x 10\^9/L or participant needed transfusion. In complete response participants dose could be restarted or increased to that before decrease if blood counts dropped to not meet CR criteria.
| ng/mL | Eltrombopag |
|---|---|
| Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: Ctrough | 20200 ± 9410 |
Cmax is the The maximum (peak) observed plasma drug concentration after dose administration. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach.
| ng/mL | Eltrombopag |
|---|---|
| Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: Cmax | 32500 ± 12300 |
Tmax is the time to reach maximum (peak) plasma drug concentration after dose administration. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach.
| hours | Eltrombopag |
|---|---|
| Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: Tmax | 5.59 ± 5.64 |
CLss/F is Apparent systemic (or total body) clearance at steady state from plasma. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach.
| Liter/hour | Eltrombopag |
|---|---|
| Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: CLss/F | 0.148 ± 0.0618 |
Collected over All-cause mortality: from first dose of study treatment up to 2 years after last dose including post-treatment long term follow up period up to 3.1 years approximately. Serious and Other Adverse Events: from first dose of study treatment until 30 days after last dose up to 1.1 years approximately.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eltrombopag | 1/36 (2.8%) | 14/36 (38.9%) | 36/36 (100%) |
| Eltrombopag (Post-treatment Long Term Follow-up) | 2/34 (5.9%) | — | — |
| Event | Eltrombopag | Eltrombopag (Post-treatment Long Term Follow-up) |
|---|---|---|
| HyperuricaemiaMetabolism and nutrition disorders | 4/36 | — |
| SepsisInfections and infestations | 3/36 | — |
| HypokalaemiaMetabolism and nutrition disorders | 2/36 | — |
| Drug-induced liver injuryHepatobiliary disorders | 1/36 | — |
| Hepatic function abnormalHepatobiliary disorders | 1/36 | — |
| Herpes zosterInfections and infestations | 1/36 | — |
| Urinary tract infectionInfections and infestations | 1/36 | — |
| Alanine aminotransferase increasedInvestigations | 1/36 | — |
| Aspartate aminotransferase increasedInvestigations | 1/36 | — |
| Blood bilirubin increasedInvestigations | 1/36 | — |
| Event | Eltrombopag | Eltrombopag (Post-treatment Long Term Follow-up) |
|---|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 18/36 | — |
| HyperuricaemiaMetabolism and nutrition disorders | 14/36 | — |
| Alanine aminotransferase increasedInvestigations | 13/36 | — |
| Blood glucose increasedInvestigations | 13/36 | — |
| PyrexiaGeneral disorders and administration site conditions | 12/36 | — |
| HyperbilirubinaemiaHepatobiliary disorders | 11/36 | — |
| Gamma-glutamyltransferase increasedInvestigations | 10/36 | — |
| HypoalbuminaemiaMetabolism and nutrition disorders | 10/36 | — |
| DiarrhoeaGastrointestinal disorders | 9/36 | — |
| Serum sicknessImmune system disorders | 9/36 | — |
| Age, Categorical(Participants) | Eltrombopag |
|---|---|
| <=18 years | 8 |
| Between 18 and 65 years | 26 |
| >=65 years | 2 |
| Age, Continuous(years) | Eltrombopag |
|---|---|
| Mean | 34.7 ± 18.97 |
| Sex: Female, Male(Participants) | Eltrombopag |
|---|---|
| Female | 21 |
| Male | 15 |
| Race (NIH/OMB)(Participants) | Eltrombopag |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 36 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Nov 2020 to primary completion in Jun 2022, 19 months.
Results were first posted in Jul 2025, 3 years 1 month after primary completion.
Of 60 phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 104. This study's 19 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Eltrombopag · Thymoglobulin · Cyclosporine